Patents Examined by Gyan Chandra
  • Patent number: 11318191
    Abstract: The present invention relates to pharmaceutical compositions of the GLP-1 peptide semaglutide comprising no more than 0.1% (w/w) phenol and above 6.4 mg/ml sodium chloride, their preparation, kits comprising such compositions as well as uses thereof.
    Type: Grant
    Filed: February 17, 2021
    Date of Patent: May 3, 2022
    Assignee: Novo Nordisk A/S
    Inventors: Dorthe Kot Engelund, Soeren Snitker, Andrew Mark Louw
  • Patent number: 11304992
    Abstract: A method for treating hyperglycemia and/or diabetes in a subject is provided. In particular, the method is directed for the treatment of patients with type 2 diabetes mellitus who have a fasting blood glucose concentration greater than about 8 mM, wherein the patient is administered a formulation comprising a GLP-1 molecule and a diketopiperazine by pulmonary inhalation with a dry powder inhalation system.
    Type: Grant
    Filed: December 19, 2019
    Date of Patent: April 19, 2022
    Assignee: MANNKIND CORPORATION
    Inventors: Donald Costello, Peter Richardson, Robert A. Baughman, Mark T. Marino
  • Patent number: 11278596
    Abstract: The present invention relates to insulin degludec for use in medicine.
    Type: Grant
    Filed: November 28, 2017
    Date of Patent: March 22, 2022
    Assignee: NOVO NORDISK A/S
    Inventors: Simon Skibsted, Kajsa Kvist
  • Patent number: 11274140
    Abstract: Provided herein are immunomodulatory proteins that exhibit neutralizing activity of BAFF and APRIL (or BAFF/APRIL heterotrimers). The immunomodulatory proteins provided herein include variant domains of Transmembrane Activator and CAML Interactor (TACI). Among provided immunodulatory proteins are TACI-Fc fusion proteins. Also provided are nucleic acid molecules encoding the immunomodulatory proteins. The immunomodulatory proteins provide therapeutic utility for a variety of immunological diseases, disorders or conditions. Also provided are compositions and methods for making and using such proteins.
    Type: Grant
    Filed: June 11, 2021
    Date of Patent: March 15, 2022
    Assignee: Alpine Immune Sciences, Inc.
    Inventors: Stacey Dillon, Mark Rixon, Lawrence Evans, Daniel William Demonte, Joseph L. Kuijper, Stanford L. Peng
  • Patent number: 11274306
    Abstract: The invention relates to methods for decreasing, inhibiting, preventing, or reducing calcification by inhibiting sortilin 1.
    Type: Grant
    Filed: October 24, 2019
    Date of Patent: March 15, 2022
    Assignee: THE BRIGHAM AND WOMEN'S HOSPITAL, INC.
    Inventors: Elena Aikawa, Claudia Goettsch, Masanori Aikawa
  • Patent number: 11267858
    Abstract: This disclosure provides a method of preventing, alleviating, or treating a condition (i.e., neutropenia) in a patient in need thereof, the condition characterized by compromised white blood cell production in the patient. The method includes administering to the patient a therapeutically effective amount of a protein complex comprising a modified human granulocyte-colony stimulating factor (hG-CSF) covalently linked to an immunoglobulin Fc region via a non-peptidyl polymer. The non-peptidyl polymer is site-specifically linked to an N-terminus of the immunoglobulin Fc region, and the modified hG-CSF comprises substitutions in at least one of Cys17 and Pro65.
    Type: Grant
    Filed: May 31, 2019
    Date of Patent: March 8, 2022
    Assignee: Spectrum Pharmaceuticals, Inc.
    Inventors: Gajanan Bhat, Shanta Chawla
  • Patent number: 11253574
    Abstract: The present invention relates to fusion proteins comprising an insulin receptor agonist fused to a human IgG Fc region through the use of a peptide linker, and the use of such fusion proteins in the treatment of diabetes. The fusion protein of the present invention has an extended time action profile and is useful for providing basal glucose control for an extended period of time.
    Type: Grant
    Filed: June 5, 2020
    Date of Patent: February 22, 2022
    Assignee: Eli Lilly and Company
    Inventors: David Bruce Baldwin, John Michael Beals, Jonathan Wesley Day, Craig Duane Dickinson, Andrew Ihor Korytko, Gregory Alan Lazar
  • Patent number: 11254724
    Abstract: The present invention relates to a novel peptide of a glucagon derivative and a composition for preventing or treating obesity comprising the peptide as an active ingredient. The glucagon derivative according to the present invention shows a more excellent activating effect with regard to both glucagon-like peptide-1 receptors and glucagon receptors compared to native glucagon, and thus can be widely used as an effective agent for treating obesity.
    Type: Grant
    Filed: November 14, 2019
    Date of Patent: February 22, 2022
    Assignee: Hanmi Pharm. Co., Ltd.
    Inventors: Sung Youb Jung, Young Jin Park, Jong Suk Lee, Jae Hyuk Choi, Chang Ki Lim, Se Chang Kwon
  • Patent number: 11246827
    Abstract: This invention provides compositions comprising a protein, an absorption enhancer, a protease inhibitor, method for treating diabetes mellitus, comprising administering same, and methods for oral administration of a protein with an enzymatic activity, comprising orally administering same.
    Type: Grant
    Filed: August 21, 2019
    Date of Patent: February 15, 2022
    Assignee: Entera Bio Ltd.
    Inventors: Miriam Kidron, Ehud Arbit
  • Patent number: 11246913
    Abstract: A suspension formulation of an insulinotropic peptide (e.g., glucagon-like peptide-1 (GLP-1) or exenatide) is described. The suspension formulation comprises (i) a non-aqueous, single-phase vehicle, comprising one or more polymer and one or more one solvent, wherein the vehicle exhibits viscous fluid characteristics, and (ii) a particle formulation comprising the insulinotropic peptide, wherein the peptide is dispersed in the vehicle. The particle formulation further includes a stabilizing component comprising one or more stabilizers, for example, carbohydrates, antioxidants, amino acids, and buffers. Devices for delivering the suspension formulations and methods of use are also described.
    Type: Grant
    Filed: June 14, 2019
    Date of Patent: February 15, 2022
    Assignee: Intarcia Therapeutics, Inc.
    Inventors: Thomas R. Alessi, Ryan D. Mercer, Catherine M. Rohloff, Bing Yang
  • Patent number: 11230584
    Abstract: This disclosure provides GLP-1/glue agon agonist peptides for the treatment of metabolic diseases, e.g., obesity.
    Type: Grant
    Filed: December 20, 2019
    Date of Patent: January 25, 2022
    Assignee: MEDIMMUNE LIMITED
    Inventors: Balaji Agoram, Madeleine Antonsson, Maria A. Bednarek, Nicole Burmeister, Lambertus Benthem, David Fairman, Maria Fritsch-Fredin, Ronald Jackson, Rasmus Jansson Lofmark, Jacqueline Metcalfe
  • Patent number: 11230585
    Abstract: A first aspect of the invention relates to a polypeptide compound of formula (I): A-C-B??(I) wherein: A is the A chain of insulin or a functional derivative or variant thereof; B is the B chain of insulin or a functional derivative or variant thereof; C is a peptide of the formula: (X1)p-(X2)n-(X3)q wherein: each X1 and X3 is independently a basic amino acid; each X2 is independently a natural or unnatural amino acid; p is 1 or 2; q is 0, 1 or 2; n is 0, 1, 2 or 3. Further aspects of the invention relate to pharmaceutical compositions comprising said polypeptide compound, and therapeutic uses thereof. Another aspect relates to the use of said polypeptide compounds in the preparation of insulin and derivatives thereof.
    Type: Grant
    Filed: September 5, 2017
    Date of Patent: January 25, 2022
    Assignee: CHEMICAL & BIOPHARMACEUTICAL LABORATORIES OF PATRA
    Inventors: Dimitrios Gatos, Alexandra Anastasiou, Kleomenis Barlos
  • Patent number: 11208488
    Abstract: The present disclosure is generally directed to compositions that include antibodies, e.g., monoclonal, chimeric, humanized antibodies, antibody fragments, etc., that specifically bind on or more epitopes within a Sortilin protein, e.g., human Sortilin or a mammalian Sortilin, and use of such compostions in preventing, reducing risk, or treating an individual in need thereof.
    Type: Grant
    Filed: September 18, 2018
    Date of Patent: December 28, 2021
    Assignee: Alector LLC
    Inventors: Arnon Rosenthal, Tina Schwabe, Michael Kurnellas, Robert Pejchal, Anthony B. Cooper
  • Patent number: 11208453
    Abstract: A two-chain insulin analogue contains a modified A-chain polypeptide and a modified B-chain polypeptide. The A-chain polypeptide comprises one or more of: a His or Glu substitution at position A8, a Glu substitution at position A14; and a Gln or Arg substitution at positon A17. The B-chain polypeptide comprises one or more of: a deletion of the amino acids at position B1, B1-B2, B1-B3, B30 or a combination thereof; an Ala or Glu substitution at position B2; a Glu substitution at position B3. The analogue exhibits thermodynamic stability in a zinc-free solution, decreased self-association, maintains biological potency, and no increased mitogenicity. The analogue exhibits resistance to chemical degradation and physical degradation. A method of treating a patient with diabetes mellitus or obesity comprises administering a physiologically effective amount of the insulin analogue or a physiologically acceptable salt thereof to a patient.
    Type: Grant
    Filed: November 21, 2017
    Date of Patent: December 28, 2021
    Assignee: Case Western Reserve University
    Inventor: Michael A. Weiss
  • Patent number: 11208452
    Abstract: The present invention relates to novel insulins or insulins analogues that are extended with predominantly sequences of polar amino acid residues in order to improve the half-life and stability of the drug substance. The invention also provides pharmaceutical compositions comprising such drug substances, and relates to the use of such drug substances for the treatment or prevention of medical conditions relating to diabetes.
    Type: Grant
    Filed: June 2, 2016
    Date of Patent: December 28, 2021
    Assignee: Novo Nordisk A/S
    Inventors: Thomas Boerglum Kjeldsen, Thomas Hoeg-Jensen, Tine Nygaard Vinther, Frantisek Hubalek, Ingrid Pettersson
  • Patent number: 11208451
    Abstract: The present invention relates to the field of biopharmaceuticals, and in particular to a protein, a protein conjugate, a pharmaceutical composition and its use for treating diabetes. The fusion protein of the present invention is obtained by linking two polypeptides, wherein one polypeptide is an interleukin-1 receptor antagonistic protein or an analogue thereof, and another polypeptide is GLP-1 receptor binding polypeptide or an analogue thereof, or an insulin receptor binding polypeptide or an analogue thereof, or a GIP receptor binding polypeptide or an analogue thereof. The fusion proteins of the present invention and conjugates thereof have a significant efficacy in treating diabetes, and can be used in a lower dose, resulting in marked reduction in side effects.
    Type: Grant
    Filed: September 10, 2019
    Date of Patent: December 28, 2021
    Inventors: Shulin Qin, Han Jie
  • Patent number: 11209434
    Abstract: The present invention is directed toward novel methods to identify as well as to treat a subject having an inflammatory disease resistant to corticosteroids.
    Type: Grant
    Filed: July 10, 2018
    Date of Patent: December 28, 2021
    Assignee: National Jewish Health
    Inventors: Donald Y. M. Leung, Elena Goleva, Lingbo Li
  • Patent number: 11186645
    Abstract: The present disclosure is generally directed to compositions that include antibodies, e.g., monoclonal, chimeric, humanized antibodies, antibody fragments, etc., that specifically bind on or more epitopes within a Sortilin protein, e.g., human Sortilin or a mammalian Sortilin, and use of such compositions in preventing, reducing risk, or treating an individual in need thereof.
    Type: Grant
    Filed: January 13, 2020
    Date of Patent: November 30, 2021
    Assignee: Alector LLC
    Inventors: Arnon Rosenthal, Tina Schwabe, Michael Kurnellas, Robert Pejchal, Anthony B. Cooper
  • Patent number: 11186623
    Abstract: The present disclosure provides recombinantly manufactured ultra-long acting insulin-Fc fusion proteins for use in treating canine diabetes. The insulin-Fc fusion proteins comprise an insulin polypeptide linked via a peptide linker to an Fc-fragment of canine origin. Based on the results obtained, creating a treatment that is amenable to low cost manufacturing, exhibits sufficient in vivo bioactivity, displays extended duration of bioactivity, does not induce anti-drug antibodies, and substantially retains is potency over multiple administrations, requires a non-obvious combination of insulin polypeptide, peptide linkers, and species-specific Fc fragment, in addition to selective mutations on one or more of these components. Exemplary ultra-long acting insulin-Fc fusion proteins, polynucleotides encoding these insulin-Fc fusion proteins, and pharmaceutical formulations of exemplary insulin-Fc fusion proteins are provided, in addition to methods of use and preparation.
    Type: Grant
    Filed: December 28, 2020
    Date of Patent: November 30, 2021
    Assignee: Akston Bioscience Corporation
    Inventors: Thomas M. Lancaster, Todd C. Zion
  • Patent number: 11174303
    Abstract: A single-chain insulin analogue comprises a B-chain insulin polypeptide connected to an A-chain insulin polypeptide by a C-domain polypeptide. The B-chain insulin polypeptide contains a Cysteine substitution at position B4. The A-chain insulin polypeptide contains a Cysteine substitution at position A10. The C-domain polypeptide is 4 to 11 amino acids long. The analogue mitigates the unfavorable activity of this 4th disulfide bridge in conventional two-chain insulin analogues resulting in a duration of insulin signaling similar to that of wild-type insulin. A method of treating a patient with diabetes mellitus comprises the administration of a physiologically effective amount of the protein or a physiologically acceptable salt thereof to a patient. Use of a single-chain insulin analogue of the present invention in an insulin delivery device (such as a pump or pen) or as part of a high-temperature polymer-melt manufacturing process.
    Type: Grant
    Filed: March 7, 2018
    Date of Patent: November 16, 2021
    Assignee: Case Western Reserve University
    Inventor: Michael A. Weiss